nnc0268-0965
Recombinant proteinexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 5, 2019 (NCT03965013)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Insulin-like growth factor I receptorSupplementation
IGF1R supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04575181 | Phase 1 | Oct 21, 2020 | Novo Nordisk |
| NCT04136067 | Phase 1 | Oct 29, 2019 | Novo Nordisk |
| NCT03965013 | Phase 1 | Jun 5, 2019 | Novo Nordisk |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 3 | 3 | 1 | 2019 |
1 organizations
Page 1 / 1